Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Intraocular Pressure Disorder Clear all
Completed No phase listed Observational

2311 TURGOR Study -Surgical Efficiency and Postoperative Corneal Clarity With Near Physiologic vs High IOP Settings

NCT07144644
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Adjusting intraocular pressure (IOP) settings
Device
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Brimonidine

NCT03959176
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Brimonidine, Tropicamide, Phenylephrine Ophthalmic Product
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01528111
View directory record Official record
Conditions
Primary Open-angle Glaucoma, Ocular Hypertension
Interventions
LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Morrow, Georgia • Memphis, Tennessee • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2015 · Synced Sep 22, 2026, 4:27 AM EDT
Not yet recruiting Not applicable Interventional

Glaucoma Drop Aids Part 2

NCT06806332
View directory record Official record
Conditions
Glaucoma, Intraocular Pressure
Interventions
Nanodropper
Device
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

The Effects of an Antioxidant Formulation on Ocular Blood Flow

NCT01930487
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
dietary supplement with antioxidants, Placebo
Dietary Supplement
Lead sponsor
ScienceBased Health
Industry
Eligibility
30 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01749904
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
BOL-303259-X, Timolol
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 22, 2026, 4:27 AM EDT
Terminated No phase listed Observational

Intraocular Pressure During Prone Spinal Surgery

NCT00176722
View directory record Official record
Conditions
Spine Surgery, Vision Impairment
Interventions
table tilt
Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT04285580
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost SR, LUMIGAN
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 22, 2026, 4:27 AM EDT
Not yet recruiting Not applicable Interventional

DSLT in Normal Tension Glaucoma (NTG) Asian Eyes

NCT07300852
View directory record Official record
Conditions
Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG), Glaucoma, Open Angle
Interventions
Direct Selective Laser Trabeculoplasty (DSLT)
Device
Lead sponsor
Ngoc Nguyen Inc.
Other
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 22, 2026, 4:27 AM EDT
Recruiting No phase listed Observational

IOP Reduction in Pigmentary Glaucoma Using DSLT

NCT07281391
View directory record Official record
Conditions
Pigmentary Dispersion Syndrome, Pigmentary Dispersion Glaucoma
Interventions
Voyager DSLT
Device
Lead sponsor
Mann Eye Institute
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye

NCT01087489
View directory record Official record
Conditions
Pain
Interventions
4% lidocaine, 3.5% ophthalmic lidocaine gel
Drug
Lead sponsor
Miami VA Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Phase 4 Interventional

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

NCT00847483
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
40
States / cities
Bellflower, California • Inglewood, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Next Generation Rocklatan

NCT06441643
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01749930
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
BOL-303259-X, Timolol
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 22, 2026, 4:27 AM EDT
Completed No phase listed Observational

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

NCT00452283
View directory record Official record
Conditions
Glaucoma, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery

NCT00840996
View directory record Official record
Conditions
Spine Surgery
Interventions
Lidocaine, placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery

NCT01786954
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Icare rebound tonometry, Tonopen applanation, Goldmann applanation
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 22, 2026, 4:27 AM EDT
Completed No phase listed Observational

Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)

NCT00691639
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
Blood Collection Only
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2009 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Results available

AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure

NCT01484951
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 1% and timolol 0.5% fixed combination eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
20 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

NCT00934089
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
PF-04217329, latanoprost vehicle, latanoprost
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Garden Grove, California • Gardena, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 22, 2026, 4:27 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Intra-observer and Inter-observer Variability With Dynamic Contour Tonometry.

NCT00818233
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Dynamic contour tonometry
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

NCT04830397
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
QLS-101, Timolol Maleate
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Albany, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

SYL040012, Treatment for Open Angle Glaucoma

NCT02250612
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate
Drug
Lead sponsor
Sylentis, S.A.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Artesia, California • Petaluma, California • Morrow, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 22, 2026, 4:27 AM EDT
Completed Not applicable Interventional

Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects

NCT01864642
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
osteopathic manipulative treatment (OMT)
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 22, 2026, 4:27 AM EDT